Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alcon Inc. Ordinary Shares (NY:ALC)

85.94 -0.41 (-0.47%)
Official Closing Price Updated: 7:00 PM EDT, May 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alcon Inc. Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019
FDA approves Alcon's Tryptyr for dry eye disease, backed by Phase 3 trials showing strong efficacy in increasing natural tear production. 
Via Benzinga
Exposures Product Safety
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease
From Alcon Inc. Investors
Via Business Wire
Alcon, American Eagle, GRAIL And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
American Eagle, Cisco Systems And 3 Stocks To Watch Heading Into Wednesday
Via Benzinga
Alcon Earnings Preview
Via Benzinga
Earnings Scheduled For February 25, 2025
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS
From Alcon Inc. Investors
Via Business Wire
Alcon Announces Results of 2025 Annual General Meeting
From Alcon Inc. Investors
Via Business Wire
Alcon Elevates Vitreoretinal and Cataract Surgery for Superior Efficiency* with UNITY VCS and UNITY CS
From Alcon Inc. Investors
Via Business Wire
Earnings Scheduled For May 13, 2025
Via Benzinga
3 Stocks Upping Dividends & 1 With A 10% Special Dividend Yield
Via MarketBeat
Alcon Publishes Agenda for 2025 Annual General Meeting
From Alcon Inc. Investors
Via Business Wire
Alcon Expands Leadership in IOL Innovation with Clareon PanOptix Pro, Delivering Best-in-Class Light Utilization and Less Light Scatter
From Alcon Inc. Investors
Via Business Wire
Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease
From Alcon Inc. Investors
Via Business Wire
Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities
From Alcon Inc. Investors
Via Business Wire
Alcon Eyes Surgical Edge With LENSAR Buyout: Details
Alcon is set to acquire LENSAR Inc. in a $356 million deal. This acquisition includes LENSAR's advanced cataract laser technologies, boosting Alcon's offerings in femtosecond laser-assisted cataract... 
Via Benzinga
Alcon Agrees to Acquire LENSAR, Inc.
From Alcon Inc. Investors
Via Business Wire
Alcon to Host 2025 Capital Markets Day
From Alcon Inc. Investors
Via Business Wire
Alcon Canada Strengthens its Commitment to Astigmatic Patients with TOTAL30 for Astigmatism Expanded Parameters
From Alcon Canada
Via Business Wire
Alcon Reports Full-Year 2024 Results, with Strong Top-line and Earnings Growth and Record Cash Generation
From Alcon Inc. Investors
Via Business Wire
Alcon Announces U.S. Launch of New SYSTANE PRO Preservative-Free, Revolutionizing Dry Eye Relief With Its Longest Lasting Formula Yet
From Alcon Inc. Investors
Via Business Wire
Alcon Announces U.S. Launch of Voyager DSLT, First-of-its-Kind Treatment for Glaucoma and Ocular Hypertension
From Alcon Inc. Investors
Via Business Wire
Apple To $253? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Alcon to Present at 2025 Annual J.P. Morgan Healthcare Conference
From Alcon Inc. Investors
Via Business Wire
Tesla To Rally More Than 11%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Alcon Reports Solid Third-Quarter 2024 Results, including Double-Digit Earnings Growth and Record Cash Generation
From Alcon Inc. Investors
Via Business Wire
Alcon Debuts Groundbreaking PRECISION7, a One-Week Replacement Contact Lens to Start and End Every Week Fresh
From Alcon Inc. Investors
Via Business Wire
Alcon Innovations on Display at AAO 2024 Demonstrate Efficiency and Performance
From Alcon Inc. Investors
Via Business Wire
Bausch Health: A Buyout Bid Could Be the Ticket to Unlock Value
The potential sale of Bausch + Lomb, Bausch Health's eye care business, could result in a financial gain for the company by reducing its debt burden. 
Via MarketBeat
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.